Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebentafusp in previously untreated metastatic uveal melanoma (TARGET-tebe)
NCT06070012Phase 2Recruiting
- Start
- Aug 2025
- Primary completion
- Sep 2028
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tebentafusp in Uveal melanoma (UM). Started Aug 2025; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT06070012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070012.